UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 679

Sortiert nach

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

Annals of oncology, 2019-12, Vol.30 (12), p.1978-1984

2019

Volltextzugriff (PDF)

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Annals of oncology, 2020-02, Vol.31 (2), p.310-317

2020

Volltextzugriff (PDF)

Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations

Annals of oncology, 2018-05, Vol.29 (5), p.1331-1333

2018

Volltextzugriff (PDF)

Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small-cell lung cancer

Annals of oncology, 2018-11, Vol.29 (11), p.2262-2263

2018

Volltextzugriff (PDF)

Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402)

Annals of oncology, 2012-09, Vol.23 (9), p.2253-2258

2012

Volltextzugriff (PDF)

Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study

Annals of oncology, 2013-05, Vol.24 (5), p.1326-1331

2013

Volltextzugriff (PDF)

Which of afatinib and gefitinib/erlotinib is the better EGFR-TKI to be followed by osimertinib?

Annals of oncology, 2018-10, Vol.29, p.viii527-viii528

2018

Volltextzugriff (PDF)

Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer

Annals of oncology, 2013-04, Vol.24 (4), p.980-985

2013

Volltextzugriff (PDF)

A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy

Annals of oncology, 2009-11, Vol.20 (11), p.1874-1880

2009

Volltextzugriff (PDF)

Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03

British journal of cancer, 2009-11, Vol.101 (9), p.1537-1542

2009

Volltextzugriff (PDF)

Overall Treatment Time of Accelerated Hyperfractionated Radiation Therapy at 45 Gy in 30 Fractions for Limited Small Cell Lung Cancer Is a Significant Prognostic Factor

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S646-S646

2014

Volltextzugriff (PDF)

3079 Randomized phase II trial of amrubicin plus irinotecan versus cisplatin plus irinotecan in chemo-naïve patients with extensivedisease small-cell lung cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01

European journal of cancer (1990), 2015-09, Vol.51, p.S623-S624

2015

Volltextzugriff (PDF)

1325 A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients (75-years-old) with advanced non-squamous, non-small cell lung cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S196-S196

2015

Volltextzugriff (PDF)

3078 Updated results and efficacy analysis according to epidermal growth factor receptor (EGFR) mutation subtypes and metastatic sites for the phase II trial of gefitinib in combination with carboplatin plus S1

European journal of cancer (1990), 2015-09, Vol.51, p.S623-S623

2015

Volltextzugriff (PDF)

Endothelium removal augments endothelium‐independent vasodilatation in rat mesenteric vascular bed

British journal of pharmacology, 2008-05, Vol.154 (1), p.32-40

2008

Volltextzugriff (PDF)

521 Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)

European journal of cancer (1990), 2015-09, Vol.51, p.S110-S111

2015

Volltextzugriff (PDF)

High-resolution CT findings of diffuse bronchioloalveolar carcinoma in 38 patients

American journal of roentgenology (1976), 1999-12, Vol.173 (6), p.1623

1999

Volltextzugriff (PDF)

9123 POSTER Final Results of a Phase II Study of Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Non-small Cell Lung Cancer – Gefitinib for Elderly Patients With Lung Adenocarcinoma

European journal of cancer (1990), 2011, Vol.47, p.S630-S630

2011

Volltextzugriff (PDF)

4001 ORAL Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients With Locally Advanced Non-small Cell Lung Cancer – a Phase III Trial of the Japan Clinical Oncology Group (JCOG0301)

European journal of cancer (1990), 2011, Vol.47, p.S273-S273

2011

Volltextzugriff (PDF)

Epidemiology of invasive meningococcal B disease in Australia, 1999–2015: priority populations for vaccination

Medical journal of Australia, 2017-11, Vol.207 (9), p.382-387

2017

Volltextzugriff (PDF)

411P Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation

Annals of oncology, 2020-11, Vol.31, p.S1402-S1403

2020

Volltextzugriff (PDF)

64P Clinical benefit of platinum doublet therapy for elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the national hospital organization in Japan

Annals of oncology, 2022-04, Vol.33, p.S61

2022

Volltextzugriff (PDF)

Analysis of predictive factors in non-small cell lung cancer patients treated with nivolumab

Annals of oncology, 2019-12, Vol.30, p.xi30

2019

Volltextzugriff (PDF)

1160P Survival impact of second-line immune checkpoint inhibitors in the elderly patients with advanced squamous non-small cell lung cancer: Post-hoc analysis from a CAPITAL study

Annals of oncology, 2022-09, Vol.33, p.S1079

2022

Volltextzugriff (PDF)

1375P Predicting chemotherapy toxicity in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the national hospital organization in Japan

Annals of oncology, 2020-09, Vol.31, p.S877-S877

2020

Volltextzugriff (PDF)

1 – 25 von 679

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(516)
Mit Volltextzugriff
(643)

Publikationsform

Sprache

Englisch
(575)
Japanisch
(191)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(281)
Life Sciences & Biomedicine
(251)
Humans
(208)
Male
(148)
Female
(146)
Oncology
(138)
Aged
(129)
Middle Aged
(112)
Lung Neoplasms - Drug Therapy
(107)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(89)
Lung Cancer
(75)
Adult
(70)
Aged, 80 And Over
(66)
Chemotherapy
(58)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(53)
Mutation
(52)
Lung Neoplasms - Pathology
(50)
Patients
(50)
General & Internal Medicine
(49)
Lung Neoplasms - Mortality
(48)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations

Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small-cell lung cancer

Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402)

Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study

Which of afatinib and gefitinib/erlotinib is the better EGFR-TKI to be followed by osimertinib?

Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer

A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy

Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03

Overall Treatment Time of Accelerated Hyperfractionated Radiation Therapy at 45 Gy in 30 Fractions for Limited Small Cell Lung Cancer Is a Significant Prognostic Factor

3079 Randomized phase II trial of amrubicin plus irinotecan versus cisplatin plus irinotecan in chemo-naïve patients with extensivedisease small-cell lung cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01

1325 A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients (75-years-old) with advanced non-squamous, non-small cell lung cancer

3078 Updated results and efficacy analysis according to epidermal growth factor receptor (EGFR) mutation subtypes and metastatic sites for the phase II trial of gefitinib in combination with carboplatin plus S1

Endothelium removal augments endothelium‐independent vasodilatation in rat mesenteric vascular bed

521 Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)

High-resolution CT findings of diffuse bronchioloalveolar carcinoma in 38 patients

9123 POSTER Final Results of a Phase II Study of Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Non-small Cell Lung Cancer – Gefitinib for Elderly Patients With Lung Adenocarcinoma

4001 ORAL Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients With Locally Advanced Non-small Cell Lung Cancer – a Phase III Trial of the Japan Clinical Oncology Group (JCOG0301)

Epidemiology of invasive meningococcal B disease in Australia, 1999–2015: priority populations for vaccination

411P Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation

64P Clinical benefit of platinum doublet therapy for elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the national hospital organization in Japan

Analysis of predictive factors in non-small cell lung cancer patients treated with nivolumab

1160P Survival impact of second-line immune checkpoint inhibitors in the elderly patients with advanced squamous non-small cell lung cancer: Post-hoc analysis from a CAPITAL study

1375P Predicting chemotherapy toxicity in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the national hospital organization in Japan

Suchergebnisse filtern